Loading…
Eledon Pharmaceuticals, Inc. is projected to rise to $5.05 by 2027, a +50% move from its current price of $3.38. ELDN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.28 | $3.38 | $3.49 | +0.12% |
| Aug 4 | $3.24 | $3.39 | $3.54 | +0.24% |
| Aug 5 | $3.21 | $3.39 | $3.58 | +0.36% |
| Aug 6 | $3.19 | $3.40 | $3.62 | +0.48% |
| Aug 7 | $3.17 | $3.40 | $3.65 | +0.60% |
| Aug 8 | $3.15 | $3.40 | $3.68 | +0.72% |
| Aug 9 | $3.14 | $3.41 | $3.70 | +0.84% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.14 | $3.41 | $3.70 | +0.84% |
| Week 2 | $3.06 | $3.44 | $3.86 | +1.68% |
| Week 3 | $3.00 | $3.47 | $4.00 | +2.54% |
| Week 4 | $2.96 | $3.49 | $4.12 | +3.40% |
| Week 5 | $2.93 | $3.52 | $4.24 | +4.27% |
| Week 6 | $2.90 | $3.55 | $4.35 | +5.14% |
| Week 7 | $2.88 | $3.58 | $4.46 | +6.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Its lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd.
for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.
Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN is a biotechnology asset currently trading at $3.31 per share, with a market capitalization of $255.49M. It ranks 3614 by market cap in the equities universe. The current price sits amid a defined price path outlined in the year-by-year forecast, which projects growth from 2026 through 2050 with rising average prices.
For example, the forecast shows an average price of $3.31 in 2026 rising to $7.09 in 2030 and reaching $45.69 on average by 2050, suggesting a long-run upside if the projections materialize.
A major floor 19.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.1% away) — a key level to hold.
The nearest ceiling, 24.6% above — a clean break opens room to run.
A major ceiling 34.1% above — clearing it would confirm fresh momentum.
Key ELDN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELDN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.41 | Sell | $3.44 | Sell |
| MA 10 | $3.59 | Sell | $3.56 | Sell |
| MA 20 | $3.79 | Sell | $3.68 | Sell |
| MA 50 | $3.76 | Sell | $3.69 | Sell |
| MA 100 | $3.55 | Sell | $3.48 | Sell |
| MA 200 | $2.90 | Buy | $3.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.88 | Neutral |
| Stoch RSI (14) | 14.83 | Buy |
| CCI (20) | -123.32 | Sell |
| Williams %R (14) | -90.79 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -15.92 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 9.21 | Buy |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | -0.37 | Sell |
| Ultimate (7,14,28) | 28.38 | Buy |
| Momentum (10) | -0.69 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 3.28 | Buy |
| ADX (14) | 14.47 | Neutral |
| ATR (14) | 0.11 | Info |
The near-term technical picture is labeled bullish, with RSI14 at 40. The stock’s short- to mid-term momentum is reflected by a 50-day simple moving average of $3.76 and a 200-day simple moving average of $2.89. Support is identified at $3.31 and resistance at $4.21, indicating a defined trading range ahead.
Over the last 30 days, the price has traded between a low of $2.67 and a high of $4.11, with volatility around 60% annualized.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.62 | $3.38 | $4.89 | 0% | Neutral | |
| $3.98 | $5.05 | $6.82 | +50% | Bullish | |
| $4.66 | $6.12 | $8.62 | +81% | Bullish | |
| $5.05 | $6.82 | $9.92 | +102% | Bullish | |
| $5.09 | $7.04 | $10.52 | +108% | Bullish | |
| $5.52 | $7.81 | $11.95 | +131% | Bullish | |
| $6.37 | $9.19 | $14.37 | +172% | Bullish | |
| $8.03 | $11.81 | $18.83 | +250% | Bullish | |
| $8.89 | $13.32 | $21.62 | +294% | Bullish | |
| $9.04 | $13.78 | $22.73 | +308% | Bullish | |
| $14.40 | $23.80 | $42.02 | +604% | Bullish | |
| $22.42 | $42.70 | $83.18 | +11.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.62 | $3.38 | $4.20 | +0.00% |
| September 2026 | $3.12 | $3.71 | $4.54 | +9.75% |
| October 2026 | $3.15 | $3.77 | $4.67 | +1.60% |
| November 2026 | $3.09 | $3.72 | $4.66 | -1.18% |
| December 2026 | $3.19 | $3.87 | $4.89 | +3.98% |
Click any year to see its month-by-month ELDN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Eledon Pharmaceuticals, Inc.'s 2026 outlook centres on $3.38, within a $1.62 to $4.89 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ELDN could reach as high as $6.82, with a base case around $5.05 and support toward $3.98 — roughly +50% from $3.38. Buyers look set to stay in control over this stretch.
Expect ELDN to range from $4.66 to $8.62 through 2028. The $6.12 average target implies a +81% move from current prices. That is up +21% on the projected 2027 average. Momentum favours further upside here.
The ELDN price prediction for 2029 points to an average of $6.82 (low $5.05, high $9.92) — a potential gain of +102% on today's $3.38. Buyers look set to stay in control over this stretch.
In 2030, ELDN is projected to trade between $5.09 and $10.52, averaging $7.04 — a potential gain of +108% from today's $3.38. That is up +3% on the projected 2029 average. Momentum favours further upside here.
Eledon Pharmaceuticals, Inc.'s 2031 outlook centres on $7.81, within a $5.52 to $11.95 range. That is up +11% on the projected 2030 average. That marks a +131% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ELDN could reach as high as $14.37, with a base case around $9.19 and support toward $6.37 — roughly +172% from $3.38. Momentum favours further upside here.
Expect ELDN to range from $8.03 to $18.83 through 2033. The $11.81 average target implies a +250% move from current prices. That is up +29% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ELDN price prediction for 2034 points to an average of $13.32 (low $8.89, high $21.62) — a potential gain of +294% on today's $3.38. Momentum favours further upside here.
In 2035, ELDN is projected to trade between $9.04 and $22.73, averaging $13.78 — a potential gain of +308% from today's $3.38. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Eledon Pharmaceuticals, Inc.'s 2040 outlook centres on $23.80, within a $14.40 to $42.02 range. That is up +73% on the projected 2035 average. That marks a +604% change versus current levels. Momentum favours further upside here.
By 2050, ELDN could reach as high as $83.18, with a base case around $42.70 and support toward $22.42 — roughly +11.6x from $3.38. Buyers look set to stay in control over this stretch.
Investing $1,000 in ELDN today (≈ 295.857988 ELDN) could be worth
$12,632.34
+$11,632.34 (+1163%) by 2050 · US Dollar
Based on the average projected ELDN price of $42.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELDNwould be worth at today's price.
$1,000 invested in ELDN on Jul 31, 2025 (≈ 317.460308 ELDN) would be worth
$1,073.02
+$73.02 (+7.3%) today · 1.07× · US Dollar
Based on a ELDN entry price of $3.15 vs. today's $3.38.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.58 | $944.13 | -5.6% |
| 1 month ago | $3.9 | $866.67 | -13.3% |
| 3 months ago | $3.69 | $915.99 | -8.4% |
| 6 months ago | $2.28 | $1,482.46 | +48.2% |
| 1 year ago | $3.15 | $1,073.02 | +7.3% |
| All time (5.0y) ago | $6.72 | $502.98 | -49.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELDN forecast.
Our base-case forecast reaches $6.80 around 2029.
Implied market cap at $6.80: $524.88M
The multi-year forecast shows a bullish trajectory, with expected average prices rising from $3.31 in 2026 to $7.09 in 2030, then to $25.22 in 2040 and $45.69 in 2050. The ROI figures reinforce the upside, moving from 0% in 2026 to 114.2% in 2030, then to 661.9% in 2040 and a striking 1280.4% by 2050. Sentiment remains bullish across most years (except 2026, which is neutral), underscoring an overall expectation of rising value over the longer term.
As with all forecasts, these are estimates and involve uncertainty, with actual results dependent on factors not guaranteed by the numbers alone.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $7.09 with a maximum of $10.71 and a minimum of $5.08, with a forecasted ROI of 114.2% and bullish sentiment.
The 2026 outlook is neutral at an average of $3.31, but from 2027 onward the forecast is bullish, with rising averages and ROI through 2050, indicating upside potential as estimates unfold.
Yes. The 2030 forecast maximum is $10.71, indicating a potential to exceed $10 within that year.
Current price is $3.31 per share and the market capitalization is $255.49M.
The 30-day range is $2.67 to $4.11.
Eledon Pharmaceuticals, Inc. Community Discussion
0Share your Eledon Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.